MECHANISMS OF DISEASE Development of Antiretroviral Drug Resistance

被引:168
作者
Wainberg, Mark A. [1 ]
Zaharatos, Gerasimos J. [1 ]
Brenner, Bluma G. [1 ]
机构
[1] McGill Univ, Jewish Gen Hosp, Lady Davis Inst, AIDS Ctr, Montreal, PQ H3T 1E2, Canada
关键词
IMMUNODEFICIENCY-VIRUS TYPE-1; HIV-1; SUBTYPE-C; TO-CHILD TRANSMISSION; SINGLE-DOSE NEVIRAPINE; REVERSE-TRANSCRIPTASE INHIBITORS; NON-B SUBTYPES; VIROLOGICAL FAILURE; IN-VITRO; K65R RESISTANCE; SOUTHERN BRAZIL;
D O I
10.1056/NEJMra1004180
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
An urgent global priority is the optimization of treatment strategies for HIV infection, regardless of geographic locale. It is reassuring that current antiretroviral strategies appear to be effective against a broad spectrum of HIV subtypes. Suboptimal therapies that include such drugs as stavudine and didanosine can facilitate the selection of the K65R mutation, which, in turn, may limit many secondary treatment options. In addition, suboptimal regimens put patients at risk for the development of NNRTI-resistance mutations. An understanding of drug-resistance patterns among non-B subtype infections may help to optimize the selection of first-line regimens and limit the acquisition of resistance. Copyright © 2011 Massachusetts Medical Society. All rights reserved.
引用
收藏
页码:637 / 646
页数:10
相关论文
共 101 条
[1]   Enfuvirtide binding domain is highly conserved in non-B HIV type 1 strains from Cameroon, West Central Africa [J].
Aghokeng, AF ;
Ewane, L ;
Awazi, B ;
Nanfack, A ;
Delaporte, E ;
Zekeng, L ;
Peeters, M .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2005, 21 (05) :430-433
[2]   HIV-1 genetic diversity in antenatal cohort, Canada [J].
Akouamba, BS ;
Viel, J ;
Charest, H ;
Merindol, N ;
Samson, J ;
Lapointe, N ;
Brenner, BG ;
Lalonde, R ;
Harrigan, PR ;
Boucher, M ;
Soudeyns, H .
EMERGING INFECTIOUS DISEASES, 2005, 11 (08) :1230-1234
[3]   Is HIV-1 evolving to a less virulent form in humans? [J].
Arien, Kevin K. ;
Vanham, Guido ;
Arts, Eric J. .
NATURE REVIEWS MICROBIOLOGY, 2007, 5 (02) :141-151
[4]   Differences in HIV Type 1 RNA Plasma Load Profile of Closely Related Cocirculating Ethiopian Subtype C Strains: C and C′ [J].
Ayele, Workenesh ;
Mekonnen, Yared ;
Messele, Tsehaynesh ;
Mengistu, Yohannes ;
Tsegaye, Aster ;
Bakker, Margreet ;
Berkhout, Ben ;
Dorigo-Zetsma, Wendelien ;
Wolday, Dawit ;
Goudsmit, Jaap ;
Coutinho, Roel ;
de Baar, Michel ;
Paxton, William A. ;
Pollakis, Georgios .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2010, 26 (07) :805-813
[5]   Rapid accumulation of nonnucleoside reverse transcriptase inhibitor-associated resistance: evidence of transmitted resistance in rural South Africa [J].
Barth, Roos E. ;
Wensing, Annemarie M. ;
Tempelman, Hugo A. ;
Moraba, Robert ;
Schuurman, Rob ;
Hoepelman, Andy I. .
AIDS, 2008, 22 (16) :2210-2212
[6]   HIV-1 strains identified in Brazilian blood donors: Significant prevalence of B/F1 recombinants [J].
Brennan, Catherine A. ;
Brites, Carlos ;
Bodelle, Pierre ;
Golden, Alan ;
Hackett, John, Jr. ;
Holzmayer, Vera ;
Swanson, Priscilla ;
Vallari, Ana ;
Yamaguchi, Julie ;
Devare, Sushil ;
Pedroso, Celia ;
Ramos, Andre ;
Badaro, Roberto .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2007, 23 (11) :1434-1441
[7]   A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors [J].
Brenner, B ;
Turner, D ;
Oliveira, M ;
Moisi, D ;
Detorio, M ;
Carobene, M ;
Marlink, RG ;
Schapiro, J ;
Roger, M ;
Wainberg, MA .
AIDS, 2003, 17 (01) :F1-F5
[8]   HIV-1 subtype C viruses rapidly develop K65R resistance to tenofovir in cell culture [J].
Brenner, Bluma G. ;
Oliveira, Maureen ;
Doualla-Bell, Florence ;
Moisi, Daniela D. ;
Ntemgwa, Michel ;
Frankel, Fernando ;
Essex, Max ;
Wainberg, Mark A. .
AIDS, 2006, 20 (09) :F9-F13
[9]   Subtype Diversity Associated with the Development of HIV-1 Resistance to Integrase Inhibitors [J].
Brenner, Bluma G. ;
Lowe, Matthew ;
Moisi, Daniela ;
Hardy, Isabelle ;
Gagnon, Simon ;
Charest, Hugues ;
Baril, Jean Guy ;
Wainberg, Mark A. ;
Roger, Michel .
JOURNAL OF MEDICAL VIROLOGY, 2011, 83 (05) :751-759
[10]  
Brenner Bluma G., 2009, HIV Therapy, V3, P583, DOI 10.2217/HIV.09.40